Differences in Neonatal Outcomes Among Premature Infants Exposed to Mother's Own Milk Versus Donor Human Milk

The Positive Effect on Preterm Infants' Feeding of Human Milk During Hospitalization and at Discharge after the Opening of a Personalized Nutrition Unit

Background: Pasteurized donor human milk must be provided when mother's own milk (MOM) is not available for preterm infants. There are concerns that human milk banks (HMBs) and the use of donor milk may potentially reduce breastfeeding rates. Objective: To compare feeding during hospitalization and at discharge before and after the opening of a HMB and to evaluate the proportion of milk provided by mothers of premature babies, comparing the intake of MOM in infants born of donor and no donor mothers. Methods: Retrospective observational cohort study. Data on milk intake and feeding at discharge of newborns <1,500 grams and/or 32 weeks gestational age. Results: There were significant differences in the intake of preterm formula (PF) between the two groups in the first 28 days of life (87.8% versus 54.2%; p = 0.000) and at discharge (34% versus 18.2%; p = 0.000). The intake of MOM during hospitalization (90.5% versus 100%; p = 0.008) and exclusive breastfeeding at discharge (18.7% versus 61.8%; p = 0.000) increased and the intake of PF (71.4% versus 33.8%; p = 0.000) and exclusive PF (EPF) at discharge decreased (27.5% versus 7,3%; p = 0.000) for babies whose mothers were or were not donors. Mothers of preterm babies donated 57.6% of the total milk received by the milk bank. Conclusion: After the opening of a HMB, there was a decrease in PF intake during hospitalization and an increase in MOM intake at discharge in preterm babies, especially for those whose mothers were milk donors.

Association of Enteral Feed Type with Neurodevelopmental and Neonatal Outcomes among Infants Born Preterm

OBJECTIVE

To examine associations between enteral feed type with neurodevelopmental and neonatal outcomes among infants born preterm.

STUDY DESIGN

This was a retrospective study of enteral feeds in the first 28 postnatal days in infants born <29 weeks of gestation from 2015 through 2020 in neonatal units of the Canadian Neonatal Network and Canadian Neonatal Follow-Up Network. Feeds were examined as a compositional variable comprised of the proportion of days fed mother's milk, donor milk, mixed feeds, and nil per os (NPO), the proportions of which sum to 1. Associations between enteral feed type with neurodevelopmental outcomes at 18 to 24 months of corrected age and neonatal morbidities were examined.

RESULTS

Our cohort included 2104 infants with a mean (SD) gestational age of 26.2 (1.5) weeks (52.9% male). Compositional data analysis revealed a 1-day reallocation from mother's milk to donor milk was associated with greater odds of cognitive (aOR 1.028, 95% CI 1.001-1.056) and language impairment (aOR 1.024, 95% CI 1.002-1.047). Replacing 1 day of mixed feeds, donor milk or NPO with mother's milk was associated with improved cognitive, language and motor development. A 1-day reallocation of NPO to either mother's milk, mixed feeds or donor milk decreased odds of significant neurodevelopmental impairment, cerebral palsy and/or necrotizing enterocolitis.

CONCLUSIONS

Donor milk in place of mother's milk was associated with poorer cognitive and language development. Providing any human milk reduced neurodevelopmental impairment and necrotizing enterocolitis with reallocations involving mother's milk yielding the most benefit. Promoting early enteral nutrition with mother's milk should be a priority in the care of infants born preterm.

Structured lactation support for mothers of very low birthweight preterm infants and establishment of human donor milk banks in German NICUs (Neo-MILK): protocol for a hybrid type 1 effectiveness-implementation cluster-randomised controlled trial

BACKGROUND

Human milk, especially mother's own milk (MOM), is vital for newborns and crucial for very low birthweight (VLBW, <1500 g) preterm infants, who face increased vulnerability. As the production of MOM may be impeded due to preterm birth, it is important to provide lactation support and establish human donor milk (HDM) banks to provide HDM when MOM is fully or initially absent. This protocol describes the design of a study evaluating the effectiveness, implementation and economic aspects of an intervention, which aims to ensure access to MOM or HDM for VLBW infants from the first day of life in German neonatal intensive care units (NICUs).

METHODS AND ANALYSIS

The hybrid type 1 effectiveness-implementation cluster-randomised controlled trial, using a stepped-wedge design, will be conducted in 15 level I and level II NICUs across Germany over 26 months. VLBW infants and their mothers will receive either standard care or the Neo-MILK intervention according to the NICU's group status. The primary outcome is the proportion of VLBW infants exclusively fed with MOM at NICU discharge. Secondary outcomes at infant level include feeding patterns, complications, length of stay and frequency of feeding with HDM. Maternal-level secondary outcomes cover lactation/breastfeeding decision and behaviour. A process evaluation and an economic analysis will accompany the study. The data set comprises survey and interview data and routinely collected data from medical records. Statistical analysis will be performed using generalised linear mixed models.

ETHICS AND DISSEMINATION

Data collection, storage and analysis comply with current data protection regulations. This study has received ethical approval from the Ethics Committee of the Medical Faculty of the University of Cologne and the local ethics committees of the participating NICUs. Results will be disseminated through peer-reviewed publications and on the project website.

TRIAL REGISTRATION NUMBER

DRKS00025058.

Initiation of Enteral Feeding with Mother's Own Milk or Donor Human Milk in Very Preterm Infants: Impact on Bronchopulmonary Dysplasia and Other Prematurity-Related Morbidities

Background: Bronchopulmonary dysplasia (BPD) is a major complication among preterm infants, and nutrition plays a crucial role in its prevention and management. While the nutritional superiority of human milk over preterm formula is well documented, comparisons of the protective benefits of mother's own milk (MOM) versus donor human milk (DHM) in preterm infants are lacking. We aim to investigate if and how the use of MOM or DHM at the initiation of enteral feeding influences the development of BPD and other respiratory outcomes. Methods: This study evaluated the incidence of BPD and other prematurity outcomes in a cohort of 159 very preterm infants (≤32 weeks GA) who commenced enteral feeding with either MOM or DHM. Results: Enteral feeding was initiated with MOM in 75.5% of the infants and DHM in 24.5%. The incidence of BPD was 24.8% (39 infants), and 10.4% (16 infants) developed moderate-to-severe BPD. Univariate and multivariate analyses revealed no significant differences between the MOM and DHM groups in the rates of BPD, other respiratory outcomes, or key prematurity-related morbidities. Conclusions: Despite the unique bioactive properties of MOM, these findings suggest that DHM is a valid alternative that does not significantly increase the incidence of BPD or other clinical outcomes. Further studies are required to determine the relative contributions of milk volumes and feeding practices to the observed findings.

Milk microbiome transplantation: recolonizing donor milk with mother's own milk microbiota

Donor human milk (DHM) provides myriad nutritional and immunological benefits for preterm and low birthweight infants. However, pasteurization leaves DHM devoid of potentially beneficial milk microbiota. In the present study, we performed milk microbiome transplantation from freshly collected mother's own milk (MOM) into pasteurized DHM. Small volumes of MOM (5%, 10%, or 30% v/v) were inoculated into pasteurized DHM and incubated at 37 °C for up to 8 h. Further, we compared microbiome recolonization in UV-C-treated and Holder-pasteurized DHM, as UV-C treatment has been shown to conserve important biochemical components of DHM that are lost during Holder pasteurization. Bacterial culture and viability-coupled metataxonomic sequencing were employed to assess the effectiveness of milk microbiome transplantation. Growth of transplanted MOM bacteria occurred rapidly in recolonized DHM samples; however, a greater level of growth was observed in Holder-pasteurized DHM compared to UV-C-treated DHM, potentially due to the conserved antimicrobial properties in UV-C-treated DHM. Viability-coupled metataxonomic analysis demonstrated similarity between recolonized DHM samples and fresh MOM samples, suggesting that the milk microbiome can be successfully transplanted into pasteurized DHM. These results highlight the potential of MOM microbiota transplantation to restore the microbial composition of UV-C-treated and Holder-pasteurized DHM and enhance the nutritional and immunological benefits of DHM for preterm and vulnerable infants. KEY POINTS: • Mother's own milk microbiome can be successfully transplanted into donor human milk. • Recolonization is equally successful in UV-C-treated and Holder-pasteurized milk. • Recolonization time should be restricted due to rapid bacterial growth.

Impact of mother's own milk vs. donor human milk on gut microbiota colonization in preterm infants: a systematic review

Background: Nutritional intake in preterm infants is associated with short- and long-term outcomes. The favorable outcomes of preterm infants who predominantly receive their mother's own milk (MOM) are thought to be mediated partly through beneficial effects on the gut microbiome. When MOM is not available, donor human milk (DHM) is recommended as the best alternative. However, DHM is less effective in preventing adverse outcomes, which may be explained by compositional differences between MOM and DHM, resulting in different microbiome development. This systematic review focuses on the effects of predominant DHM vs. MOM feeding on the gut microbiota composition in preterm infants. Methods: A comprehensive search was conducted across MEDLINE, Embase, and Cochrane databases. Eight out of the 717 publications identified were included. Data on gut microbiota composition, alpha diversity, and taxonomic differences between DHM- and MOM-fed preterm infants were extracted and analyzed. Results: The microbiome composition was distinct between the two feeding groups. Alpha diversity measures were lower in DHM-fed infants, particularly when preterm formula (PF) was also provided. DHM-fed infants showed higher abundances of Staphylococcaceae and Clostridiaceae, and lower abundances of Bacteroidetes and Bifidobacterium. Conclusion: The observed gut microbiome differences in DHM-fed preterm infants have previously been linked to adverse health outcomes. This underlines the importance of increasing the awareness of MOM intake in preterm infants. Further studies should explore the mechanisms through which human milk affects health outcomes.

Maternity care practices supportive of breastfeeding in U.S. advanced neonatal care units, United States, 2022

OBJECTIVE

To describe breastfeeding-supportive practices in U.S. maternity hospitals with advanced neonatal care units (ANCU).

STUDY DESIGN

Using 2022 mPINC data, we calculated the percent of hospitals reporting (1) breastfeeding-supportive practices for "most" (≥80%) mother-baby dyads in ANCUs, by hospital demographic characteristics and (2) infant receipt of mother's own milk or donor milk at any time while in the ANCU, by ANCU level.

RESULTS

More than 90% of hospitals reported that "most" mothers (≥80%) were advised on some breastfeeding-supportive practices. Fewer hospitals reported that "most" mothers expressed milk within one hour of birth (37%) or that kangaroo care was practiced for "most" eligible newborns (63%). Receipt of mother's own milk varied by unit level and state.

CONCLUSION

Breastfeeding-supportive practices requiring the technical competency of healthcare providers (e.g., early milk expression, kangaroo care) are less likely to be implemented in ANCU settings compared to practices centered around providing advice or education.

Early human milk feeding: Relationship to intestinal barrier maturation and postnatal growth

OBJECTIVES

Early exposure to mother's own milk (MOM) promotes intestinal barrier maturation in preterm infants. We hypothesized (1) donor human milk (DHM) supplementation reduces intestinal permeability (IP) similar to exclusive MOM and (2) early HM exposure and low IP at 7-10 days postnatal age (PNA) are associated with improved growth outcomes.

METHODS

IP was measured by the standard sugar absorption test (SAT) in infants <33 weeks gestation between 7-10 days PNA. Nutritional and anthropometric data were recorded. Postnatal growth failure (PNGF) was defined as a decrease in weight z-score >1 from birth to discharge to home.

RESULTS

Of 158 preterm infants, the mean (SD) gestational age was 29.9(2.3) weeks and birthweight 1388(424) g. Diet prior to SAT was exclusive MOM [N = 55(35%)], DHM ± MOM [N = 52(33%)], or preterm formula±MOM [N = 51(32%)]. The mean Lactulose(La)/Rhamnose(Rh) ratio was lower in the exclusive MOM [0.06(0.07)] and DBM ± MOM [0.05(0.07)] groups compared to the preterm formula±MOM group [0.11(0.11)], p < 0.01). Cumulative intake >150 ml/kg MOM ± DHM, but not preterm formula within 7-10 days PNA was associated with early intestinal barrier maturation. Low IP was not associated with lower risk of PNGF at discharge.

CONCLUSIONS

Low IP is associated with cumulative intake of MOM alone or supplemented with DHM > 150 ml/kg within 7-10 days PNA.

CLINICAL TRIAL REGISTRATION

Clinicaltrials.gov NCT01756040 ; web link to study on registry: https://clinicaltrials.gov/study/NCT01756040 .

IMPACT

Key message Early intestinal barrier maturation is associated with cumulative intake of exclusive MOM alone or supplemented with DHM > 150 ml/kg within 7-10 days after birth, but is not associated with lower risk of PNGF at time of discharge. What it adds to existing literature? This observational study is the first study to demonstrate that supplemental DHM promotes intestinal barrier maturation similar to MOM alone. What is the impact? The findings underscore the importance of early introduction of human milk feeds as MOM or MOM supplemented with DHM in sufficient volume to promote early intestinal barrier maturation.

Efficacy and safety of acupuncture for postpartum hypogalactia: protocol for a systematic review and meta-analysis

INTRODUCTION

Breast milk is recognised as the best natural food for neonates, but many women experience postpartum hypogalactia (PH). Randomised trials have found that acupuncture exert therapeutic effect on women with PH. However, systematic reviews on the efficacy and safety of acupuncture are still lacking; therefore, this systematic review aims to evaluate the efficacy and safety of acupuncture for PH.

METHODS AND ANALYSIS

Six English databases (PubMed, Cochrane Library, EMBASE, EBSCO, Scopus, and Web of Science) and four Chinese databases (China National Knowledge Infrastructure, Wan-Fang, Chinese Biomedical Literature and Chinese Scientific Journal) will be systematically searched from their establishment to 1 September 2022. Randomised controlled trials of the efficacy of acupuncture for PH will be reviewed. The study selection, data extraction and research quality evaluation will be conducted independently by two reviewers. The primary outcome is the change in serum prolactin level from baseline to the end of treatment. Secondary results include milk secretion volume, total effectiveness rate, degree of mammary fullness, rate of exclusive breast feeding, and adverse events. A meta-analysis will be performed using RevMan V.5.4 statistical software. Otherwise, a descriptive analysis will be conducted. The risk of bias will be assessed using the revised Cochrane risk-of-bias tool.

ETHICS AND DISSEMINATION

This systematic review protocol does not require ethical approval because it does not include private information/data of the participants. This article will be published in peer-reviewed journals.

PROSPERO REGISTRATION NUMBER

CRD42022351849.